Literature DB >> 3120185

Prevention of occlusive coronary artery thrombosis by a murine monoclonal antibody to porcine von Willebrand factor.

D A Bellinger1, T C Nichols, M S Read, R L Reddick, M A Lamb, K M Brinkhous, B L Evatt, T R Griggs.   

Abstract

A murine monoclonal antibody (mAb) against porcine von Willebrand factor (vWF) induced an antithrombotic state in normal pigs. Thrombosis was induced by a standard procedure of stenosis and mechanical injury of the artery. The mAb was an IgG1 kappa that inhibited vWF-induced platelet aggregation at a titer of 1:6250 and bound to immobilized vWF at a maximal dilution of 1:512,000. The antibody did not affect two other vWF functions, platelet adhesion and binding of coagulant factor VIII (factor VIII:C). The antithrombotic state was characterized by a prolonged bleeding time and lack of plasma vWF activity, but with near-normal levels of factor VIII:C and von Willebrand antigen. The circulating Ag.mAb complex demonstrated a multimeric distribution comparable to that of native plasma vWF. Three groups of pigs were studied: group A consisted of nine untreated animals, eight of which developed occlusive coronary thrombosis; group B, four treated animals with a long bleeding time, none of which developed occlusive thrombosis; and group C, two animals with preexisting thrombosis treated with mAb, in which stable blood flow was reestablished. Morphologically, the group B animals showed adherent platelets covering the injured intima but no thrombosis. This mAb is an antithrombotic agent that prevents platelet thrombosis without affecting intrinsic platelet function.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3120185      PMCID: PMC299486          DOI: 10.1073/pnas.84.22.8100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  Plasma levels of platelet aggregating factor/vom Willebrand factor in various species.

Authors:  K M Brinkhous; B D Thomas; S A Ibrahim; M S Read
Journal:  Thromb Res       Date:  1977-09       Impact factor: 3.944

2.  Venom coagglutinin: an activator of platelet aggregation dependent on von Willebrand factor.

Authors:  M S Read; R W Shermer; K M Brinkhous
Journal:  Proc Natl Acad Sci U S A       Date:  1978-09       Impact factor: 11.205

3.  Role of von Willebrand factor in platelet adhesion to the subendothelium.

Authors:  D Meyer; H R Baumgartner
Journal:  Br J Haematol       Date:  1983-05       Impact factor: 6.998

4.  Use of venom coagglutinin and lyophilized platelets in testing for platelet-aggregating von Willebrand factor.

Authors:  K M Brinkhous; M S Read
Journal:  Blood       Date:  1980-03       Impact factor: 22.113

5.  Use of monoclonal antibodies in an enzyme immunoassay for factor VIII-related antigen.

Authors:  L A Bradley; E L Franco; H M Reisner
Journal:  Clin Chem       Date:  1984-01       Impact factor: 8.327

6.  Effect of carbon monoxide on atherogenesis in normal pigs and pigs with von Willebrand's disease.

Authors:  D L Sultzer; K M Brinkhous; R L Reddick; T R Griggs
Journal:  Atherosclerosis       Date:  1982-06       Impact factor: 5.162

7.  Platelet adhesion to damaged coronary arteries: Comparison in normal and von Willebrand disease swine.

Authors:  R L Reddick; T R Griggs; M A Lamb; K M Brinkhous
Journal:  Proc Natl Acad Sci U S A       Date:  1982-08       Impact factor: 11.205

8.  The complex multimeric composition of factor VIII/von Willebrand factor.

Authors:  Z M Ruggeri; T S Zimmerman
Journal:  Blood       Date:  1981-06       Impact factor: 22.113

9.  Blood flow reductions in stenosed canine coronary arteries: vasospasm or platelet aggregation?

Authors:  J D Folts; K Gallagher; G G Rowe
Journal:  Circulation       Date:  1982-02       Impact factor: 29.690

10.  Botrocetin (venom coagglutinin): reaction with a broad spectrum of multimeric forms of factor VIII macromolecular complex.

Authors:  K M Brinkhous; M S Read; W A Fricke; R H Wagner
Journal:  Proc Natl Acad Sci U S A       Date:  1983-03       Impact factor: 11.205

View more
  12 in total

Review 1.  Developments in antithrombotic therapy: state of the art anno 1996.

Authors:  H ten Cate; M T Nurmohamed; J W ten Cate
Journal:  Pharm World Sci       Date:  1996-12

Review 2.  von Willebrand factor.

Authors:  Z M Ruggeri
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

3.  Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease.

Authors:  K M Brinkhous; U Hedner; J B Garris; V Diness; M S Read
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

4.  Distinct abnormalities in the interaction of purified types IIA and IIB von Willebrand factor with the two platelet binding sites, glycoprotein complexes Ib-IX and IIb-IIIa.

Authors:  L De Marco; M Mazzucato; D De Roia; A Casonato; A B Federici; A Girolami; Z M Ruggeri
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

5.  Identification of a point mutation in type IIB von Willebrand disease illustrating the regulation of von Willebrand factor affinity for the platelet membrane glycoprotein Ib-IX receptor.

Authors:  J Ware; J A Dent; H Azuma; M Sugimoto; P A Kyrle; A Yoshioka; Z M Ruggeri
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

Review 6.  Novel antithrombotic drugs in development.

Authors:  M Verstraete; P Zoldhelyi
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

7.  Function of von Willebrand factor after crossed bone marrow transplantation between normal and von Willebrand disease pigs: effect on arterial thrombosis in chimeras.

Authors:  T C Nichols; C M Samama; D A Bellinger; J Roussi; R L Reddick; M Bonneau; M S Read; O Bailliart; G G Koch; M Vaiman
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

Review 8.  Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.

Authors:  Timothy C Nichols; Aaron M Dillow; Helen W G Franck; Elizabeth P Merricks; Robin A Raymer; Dwight A Bellinger; Valder R Arruda; Katherine A High
Journal:  ILAR J       Date:  2009

9.  A comparative study of the antithrombotic effect of aurintricarboxylic acid on arterial thrombosis in rats and guinea pigs.

Authors:  Y Takiguchi; M Shimazawa; M Nakashima
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

10.  Porcine von Willebrand disease and atherosclerosis. Influence of polymorphism in apolipoprotein B100 genotype.

Authors:  T C Nichols; D A Bellinger; K E Davis; G G Koch; R L Reddick; M S Read; J Rapacz; J Hasler-Rapacz; K M Brinkhous; T R Griggs
Journal:  Am J Pathol       Date:  1992-02       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.